Aerosolized Survanta in Treatment of Respiratory Distress Syndrome

Comparison of the Need for Second Dose of Survanta Administration in Two Groups of Neonates with the Gestational Age of 28/07 to 32/07 Weeks with Respiratory Distress Syndrome Followed by the First Dose of Survanta Administration in Control Group via Intubation and in Interventional Group via Aerosolization

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120728010430N10

Enrollment

Registered

2020-09-04

Start date

2019-12-21

Completion date

Unknown

Last updated

2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The effect of Aerosolized Surfactant on hyaline membrane disease. Hyaline membrane disease

Interventions

Intervention 1: Intervention group: this group includes neonates with the gestational age of 28/07 to 32/07 weeks with Respiratory Distress Syndrome Administered Survanta via Aerosolization. Intervent

Eligibility

Sex/Gender

All

Age

1 Days to 2 Days

Inclusion criteria

Inclusion criteria: Clinical Symptoms of Respiratory Distress Syndrome (Tachypnea, Intercostal Retraction, Nasal Flaring, Grunting) Neonates under nCPAP (CDP=5 cm H2O; FiO2=0.4 to maintain SpO2 at 89-95% in the right hand) Filling out the written consent form

Exclusion criteria

Exclusion criteria: Respiratory tract anomalies Cardiothorasic malformations and Craniofacial anomalies Airleak syndromes Perinatal Asphyxia (5-minute Apgar score=0-3; Umblical Cord pH<7 and Bicarbonate<12)

Design outcomes

Primary

Measure	Time frame
The need for Second Dose of Survanta Administration. Timepoint: Six hours after the First Dose of Syrvanta Administration. Method of measurement: Fraction of Inspired Oxygen under nCPAP.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Sadeghnia

Esfahan University of Medical Sciences

asadeghnia@gmail.com+98 31 3668 0048

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026